Why the study?
New interventions are still needed to improve cardiovascular disorders associated with metabolic syndrome driven by high-fat diet intake.
Does GYY-4137 improve vascular function and metabolic parameters in spontaneously hypertensive rats fed a high-fat diet?
Does GYY-4137 improve vascular function and metabolic parameters in spontaneously hypertensive rats fed a high-fat diet?
In a rat model of hypertension and metabolic syndrome, the hydrogen sulfide donor GYY-4137 reduced blood pressure and improved vascular function by restoring NO signaling and suppressing inflammation.
Answers are grounded in this paper and cite their sources.
GYY-4137 effects in HFD models remain hypothesis-generating; leaves open clinical translation in metabolic syndrome.
BACKGROUND/OBJECTIVES: Metabolic syndrome is one of the leading causes of mortality worldwide, with high-fat diet (HFD) intake being a significant driving force. Despite long-term research, new interventions are still being sought to improve cardiovascular disorders associated with metabolic syndrome. METHODS: S donor, we evaluated the effects of 3 weeks of treatment with GYY-4137 on systolic blood pressure (sBP), cardiac parameters, adiposity, selected plasma markers, and the vascular function of the thoracic aortas (TAs) and mesenteric arteries (MAs) isolated from male spontaneously hypertensive rats (SHRs) fed an HFD for 8 weeks. RESULTS: HFD administration induced cardiac remodeling, increased adiposity, and decreased adrenergic contractility in both TAs and MAs. Moreover, although high-fat intake improved TAs relaxation, it decreased aortic protein expression of endothelial NO synthase and the involvement of NO in vasoactive responses of both TAs and MAs. In addition, protein expression of inducible NOS and tumor necrosis factor alpha (TNFα) in aortas was increased, as were plasma levels of chemerin, which has been proposed as a possible link among metabolic and vascular disorders and inflammation. Treatment with GYY-4137 reduced sBP, improved relaxation of the MAs, partially restored the contractility of the TAs, generally restored NO signaling, and decreased the protein expression of the inducible NOS and TNFα, as well as plasma chemerin levels. CONCLUSIONS: S-releasing donor could partially ameliorate the metabolic changes induced by increased fat intake during essential hypertension and trigger beneficial vasoactive effects associated with the NO signaling restoration and suppression of inflammation.
No takes yet. Share an insight, caveat, or question.
Aydemir et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: